Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envelope glycoprotein 120 (gp120) is a surface-exposed glycoprotein of the Human Immunodeficiency Virus (HIV), essential for viral entry into host cells. It is part of the envelope spike complex, which also includes gp41, and plays a central role in virus attachment and membrane fusion. Gp120 mediates HIV entry through sequential interactions: binding to CD4 receptors, followed by CCR5/CXCR4 coreceptors, triggering membrane fusion. It is a highly immunogenic but variable protein, targeted for vaccine development and antiviral therapies.
Small-molecule inhibitors targeting entry steps are under investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope Glycoprotein 120 (gp120).